Merck &Co (MRK) Stock Moves Higher By 3% This Week Amid Recent News: Should You Buy Or Not?

Acceleron Pharma Inc is a biopharmaceutical company that focuses on developing drugs for rare diseases. MRK stock surges from September 28, it was trading at $72.72 to $75.80. Merck will acquire Acceleron for about $180 per share in cash, a premium of about 2.6% to the company’s closing price on Wednesday. Acceleron is a biopharmaceutical company focused on the discovery and development of novel medicines for treating blood-related disorders.

Merck & Co Sotatercept is a drug that is being developed to treat patients with a rare type of heart disease known as pulmonary arterial hypertension. The rare disease market is expected to grow at 5% a year on average in the next couple of years due to the increasing number of new drugs being developed for these conditions. Johnson & Johnson purchased Actelion in 2017 for about $30 billion. The company then launched a clinical trial for a treatment for pulmonary arterial hypertension.

Anthony Gonzales

Biotech, Tech, and Crypto reporterAnthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.